Resource Summary Report

Generated by NIF on Sep 17, 2026

KLE

RRID:CVCL_1329
Type: Cell Line

Proper Citation

RRID:CVCL_1329

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1329

Proper Citation: RRID:CVCL_1329

Description: Cell line KLE is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Type II endometrial adenocarcinoma

Defining Citation: PMID:1541432, PMID:2436984, PMID:6706226, PMID:7798295, PMID:8123477, PMID:9887230, PMID:12893190, PMID:20164919, PMID:20215515, PMID:22460905, PMID:22710073, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31395879, PMID:33174010, PMID:35839778

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: KLE

Cross References: BTO:BTO_0005079, CLO:CLO_0007104, EFO:EFO_0002220, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-1622, BCRJ:0365, BioGRID_ORCS_Cell_line:622, BioSample:SAMN03473101, BioSample:SAMN10987617, cancercelllines:CVCL_1329, CCRID:1101HUM-PUMC000379, CCRID:4201HUM-

CCTCC00115, CCTCC:GDC0115, Cell_Model_Passport:SIDM00686, ChEMBL-Cells:CHEMBL3308518, ChEMBL-Targets:CHEMBL2366239, CLS:305051, Cosmic:713476, Cosmic:713493, Cosmic:809133, Cosmic:846179, Cosmic:871554, Cosmic:889114, Cosmic:924187, Cosmic:980636, Cosmic:1007161, Cosmic:1066225, Cosmic:1070809, Cosmic:1177622, Cosmic:1223485, Cosmic:1241349, Cosmic:1576461, Cosmic:1622900, Cosmic:1696759, Cosmic:2030477, Cosmic:2646620, Cosmic:2702442, Cosmic-CLP:924187, DepMap:ACH-000293, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:924187, GEO:GSM374973, GEO:GSM375432, GEO:GSM844574, GEO:GSM844575, GEO:GSM887211, GEO:GSM888284, GEO:GSM1669987, GEO:GSM3161718, GEO:GSM3161719, IARC_TP53:1113, IGRhCellID:KLE, IZSLER:BS TCL 230, LiGeA:CCLE_909, LINCS_LDP:LCL-1505, PharmacoDB:KLE_750_2019, PRIDE:PXD030304, Progenetix:CVCL_1329, PubChem_Cell_line:CVCL_1329, Wikidata:Q54900024

ID: CVCL_1329

Record Creation Time: 20220427T220704+0000

Record Last Update: 20260913T004658+0000

Ratings and Alerts

No rating or validation information has been found for KLE.

No alerts have been found for KLE.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Tao H, et al. (2026) NSD1-Mediated PPAR?? Methylation Enhances PTEN Activity to Suppress Glycolysis and Tumor Progression in Endometrial Cancer. Cancer research, 86(10), 2464.

Bandi DSR, et al. (2026) ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma. bioRxiv : the preprint server for biology.

Huang TT, et al. (2026) DHX9 inhibition enhances paclitaxel sensitivity by inducing mitotic failure in ovarian and endometrial cancers. Molecular cancer therapeutics.

Peng J, et al. (2026) CBLC-mediated ubiquitination stabilizes METTL1, enhances N7-methylguanosine modification of ESRRA, and promotes the progression of endometrial cancer. International journal of biological macromolecules, 369, 152809.

Tedeschi A, et al. (2025) Pan-KRAS Inhibitors BI-2493 and BI-2865 Display Potent Antitumor Activity in Tumors with KRAS Wild-type Allele Amplification. Molecular cancer therapeutics, 24(4), 550.

Yang Z, et al. (2025) Functional Profiling of p53 and RB Cell Cycle Regulatory Proficiency Suggests Mechanism-Driven Molecular Stratification in Endometrial Carcinoma. Cancer research communications, 5(4), 719.

Song L, et al. (2025) Penfluridol targets septin7 to suppress endometrial cancer by septin7-Orai/IP3R-Ca2+-PIK3CA pathway. iScience, 28(1), 111640.

Carballo EV, et al. (2025) The Impact of JAK1 Pathogenic Variants and MHC-I Expression on Response to Immune Checkpoint Inhibition in Endometrial Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(24), 5294.

Santiappillai NT, et al. (2025) Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. Molecular systems biology, 21(8), 983.

Nelson BE, et al. (2025) Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(18), 3864.

Tani T, et al. (2024) TREX1 Inactivation Unleashes Cancer Cell STING-Interferon Signaling and Promotes Antitumor Immunity. Cancer discovery, 14(5), 752.

Gjorgoska M, et al. (2024) Pre-receptor regulation of 11-oxyandrogens differs between normal and cancerous endometrium and across endometrial cancer grades and molecular subtypes. Frontiers in endocrinology, 15, 1404804.

Gong X, et al. (2024) Pyroptosis-associated genes and tumor immune response in endometrial cancer. Discover oncology, 15(1), 433.

Aljardali MW, et al. (2024) Nucleolar Localization of the RNA Helicase DDX21 Predicts Survival Outcomes in Gynecologic Cancers. Cancer research communications, 4(6), 1495.

Patil A, et al. (2023) A disordered region controls cBAF activity via condensation and partner recruitment. Cell, 186(22), 4936.

Zhang W, et al. (2023) HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. Cell reports, 42(11), 113352.

Nargund AM, et al. (2022) Chromatin Rewiring by Mismatch Repair Protein MSH2 Alters Cell Adhesion Pathways and Sensitivity to BET Inhibition in Gastric Cancer. Cancer research, 82(14), 2538.

Pavli?? R, et al. (2021) In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway. Frontiers in molecular biosciences, 8, 743403.

Yeh YM, et al. (2021) MET Mutation Is a Potential Therapeutic Target for Advanced Endometrial Cancer. Cancers, 13(16).

Xu H, et al. (2021) CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell reports. Medicine, 2(9), 100394.